JPRN-jRCT1031220116进行中（未招募）未知
Real-world Effectiveness and Safety of Trifluridine/Tipiracil plus bevacizumab in Metastatic Colorectal Cancer: A retrospective observational study using an administrative database
Taiho Pharmaceutical Co., Ltd. Medical Affairs Division0 个研究点目标入组 11,962 人开始时间: 2022年6月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 11,962
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with CRC aged over 20 years who were diagnosed between May 2014 and January 2021 by using the International Classification of Diseases, 10th revision (ICD-10) codes in the database.
- •-Patients who received FTD/TPI and/or regorafenib.
排除标准
- •1) FTD/TPI- or regorafenib-treated patients with diseases other than CRC;
- •2) patients who received other chemotherapy except bevacizumab simultaneously with FTD/TPI
- •3) patients who received other chemotherapy simultaneously with regorafenib.
研究者
相似试验
尚未招募
不适用
Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000041621The 22nd Century Cutting-Edge Medical Informaion Technology Organization239
进行中（未招募）
1 期
Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a secondline therapy in patients with bile duct cancerPatients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment.EUCTR2018-002936-26-DEHeinrich-Heine-University Düsseldorf28
已完成
4 期
A clinical trial to study the effect of Triflusal in Aspirin resitant patientsCTRI/2011/04/001679Glenmark Pharmaceuticals Lts40
尚未招募
Unknown
A retrospective observational study of trifluridine tipiracil plus minus bevacizumab in pretreated mCRC patients with MSI-H MMR-D metastatic colorectal cancerJPRN-UMIN000051378The 22nd Century Cutting-Edge Medical Informaion Technology Organization15
进行中（未招募）
1 期
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroesophageal cancerCTIS2023-508724-35-00nicancer73